| Autor: |
Zloza A; Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08901, USA., Karolina Palucka A; The Jackson Laboratory for Genomic Medicine, Farmington, CT, 06032, USA., Coussens LM; Knight Cancer Institute at Oregon Health & Science University, Portland, OR, 97239, USA., Gotwals PJ; Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, 02139, USA., Headley MB; University of California San Francisco, San Francisco, CA, 94143, USA., Jaffee EM; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 21287, USA., Lund AW; Oregon Health & Science University, Portland, OR, 97239, USA., Sharpe AH; Harvard Medical School, Boston, MA, 02115, USA., Sznol M; Yale School of Medicine, New Haven, CT, 06520, USA., Wainwright DA; Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA., Wong KK; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA., Bosenberg MW; Yale School of Medicine, 15 York Street, St LMP 5031, New Haven, CT, 06510, USA. marcus.bosenberg@yale.edu. |
| Abstrakt: |
Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Society for Immunotherapy of Cancer (SITC) convened a workshop titled, "Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy" as part of the SITC 31st Annual Meeting and Associated Programs on November 10, 2016 in National Harbor, MD. The workshop focused on key issues in optimizing models for cancer immunotherapy research, with discussions on the strengths and weaknesses of current models, approaches to improve the predictive value of mouse models, and advances in cancer modeling that are anticipated in the near future. This full-day program provided an introduction to the most common immunocompetent and humanized models used in cancer immunology and immunotherapy research, and addressed the use of models to evaluate immune-targeting therapies. Here, we summarize the workshop presentations and subsequent panel discussion. |
Full text from SpringerLink